A federal judge has granted final approval to SmithKline Beecham's $65 million settlement of an antitrust class action by consumers who said they paid inflated prices for Paxil, a popular anti-depressant. The suit alleged that SmithKline illegally maintained a monopoly by filing a series of "sham" patent suits to delay generic versions from reaching market. The judge also awarded $19 million in attorney fees to plaintiffs lawyers who logged more than 17,000 hours on the case since December 2000.
$65 Million Settlement OK'd in Paxil Antitrust Lawsuit
The Legal Intelligencer
April 27, 2005